These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12427703)

  • 1. Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.
    Mamdani M; Rochon P; Laupacis A; Anderson G
    CMAJ; 2002 Nov; 167(10):1125-6. PubMed ID: 12427703
    [No Abstract]   [Full Text] [Related]  

  • 2. The cox-2 inhibitors.
    Strassels S
    J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating pain with COX-2 inhibitors.
    Rodgers E
    Nurse Pract; 1999 Nov; 24(11):95-6, 99-100, 102. PubMed ID: 10618817
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice.
    Russo P; Capone A; Attanasio E; Baio G; Di Martino M; Degli Esposti L; Marchetta F; Buda S; Degli Esposti E; Caprino L
    Rheumatology (Oxford); 2003 Jul; 42(7):879-87. PubMed ID: 12730549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between COX-2-specific inhibitors: clinical and economic implications.
    Sonnenblick EH
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective COX-2 inhibition.
    Silas S; Clegg DO
    Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
    [No Abstract]   [Full Text] [Related]  

  • 10. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

  • 11. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug].
    MMW Fortschr Med; 2000 Nov; 142(44):53. PubMed ID: 11107811
    [No Abstract]   [Full Text] [Related]  

  • 13. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
    Moride Y; Ducruet T; Rochon S; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
    Stephens J; Laskin B; Pashos C; Peña B; Wong J
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V; Hutchins B
    Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
    Harley C; Wagner S
    Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.